CAS: 91-81-6; N'-Benzyl-N,N-Dimethyl-N'-Pyridin-2-Ylethane-1,2-Diamine

上下游产品

2-(N-benzyl-pyridin-2-yl-amino)ethanol dimethyl amine 2-chloropyridine N,N-dimethyl-N'-(pyridine-2-yl)ethane-1,2-diamine[2-(Benzyl-pyridin-2-yl-amino)-ethyl]-((2R,3R,4S,5S,6S)-6-carboxy-3,4,5-trihydroxy-tetrahydro-pyran-2-yl)-dimethyl-ammonium; chloride N'-benzyl-N,N-dimethyl-N'-[2]pyridyl-ethylenediamine-N-oxideN'-benzyl-N,N-dimethyl-N'-[2]pyridyl-ethylenediamine-N-oxide

📜2-氯吡啶置于lithium Amide体系中,用 乙腈 作为反应溶剂,化学反应 20.08H,反应生成 曲吡那敏
参考文献:Design,Synthesis,And Biological Evaluation Of Novel Fak Scaffold Inhibitors Targeting The Fak-vegfr3 Protein-protein Interaction
标题:Design,Synthesis,And Biological Evaluation Of Novel Fak Scaffold Inhibitors Targeting The Fak-vegfr3 Protein-protein Interaction
摘要:Focal Adhesion Kinase (Fak) And Vascular Endothelial Growth Factor Receptor 3 (Vegfr3) Are Tyrosine Kinases,Which Function As Key Modulators Of Survival And Metastasis Signals In Cancer Cells. Previously,We Reported That Small Molecule Chlorpyramine Hydrochloride (C4) Specifically Targets The Interaction Between Fak And Vegfr3 And Exhibits Anti-Tumor Efficacy. In This Study,We Designed And Synthesized A Series Of 1 (C4) Analogs On The Basis Of Structure Activity Relationship And Molecular Modeling. The Resulting New Compounds Were Evaluated For Their Binding To The Fat Domain Of Fak And Anti-Cancer Activity. Amongst All Tested Analogs,Compound 29 Augmented Anti-Proliferative Activity In Multiple Cancer Cell Lines With Stronger Binding To The Fat Domain Of Fak And Disrupted The Fak-Vegfr3 Interaction. In Conclusion,We Hope That This Work Will Contribute To Further Studies Of More Potent And Selective Fak-Vegfr3 Protein-Protein Interaction Inhibitors.
DOI:10.1016/j.Ejmech.2014.04.041

专利信息

专利号:US-11629150-B2
优先权日:2016-07-01
标题:Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
发明人：SMITH ALEXANDER; WHITE HANNAH S; TAVARES FRANCIS XAVIER; KRASUTSKY SERGIY; CHEN JIAN-XIE; DORROW ROBERTA L; ZHONG HUA
权利人:G1 THERAPEUTICS INC
摘要:This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

专利号:US-7919505-B2
优先权日:2006-07-11
标题 :Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
发明人：TING PAULINE C; LEE JOE F; FENG KUNG-I; REEDER MICHAEL R; TRZASKA SCOTT T; ZHU MAN; MAO CHEN; FILIPOV DIMITAR L; ZARKADAS DIMITRIOS N
权利人:SCHERING CORP
摘要:The present invention relates to the compound of the formula n nTo methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人：PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEs†). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

专利号:EP-4198027-A1
优先权日:2021-12-14
标题:Sustainable process for the synthesis of molecules with antihistamine activity in unconventional biodegradable solvents (deep eutectic solvents)
发明人：QUIVELLI ANDREA FRANCESCA; CAPRIATI VITO; PERNA FILIPPO MARIA; VITALE PAOLA; ROSSI FEDERICO VITTORIO; GARCÃ A - Ã LVAREZ JOAQUÃ N
权利人:UNIV DEGLI STUDI DI BARI; UNIV OVIEDO
摘要:The present invention relates to a sustainable synthetic process for obtaining ethylenediamines molecules with antihistamine activity whose production costs are considerably reduced by employing unconventional biodegradable solvents, such as the Deep Eutectic Solvents, with considerable advantages from a point of view both of the environmental and economic impact.

专利号:WO-2023075715-A1
优先权日:2021-10-26
标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
发明人：OYTUN FARUK; CAN EFE
权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.

专利号:US-11787803-B2
优先权日:2017-09-15
标 题 :Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
发明人：SCHILLER SHAWN E R; HERBERTZ TORSTEN; LI HONGBIN; GRAVES BRADFORD; MISCHKE STEVEN; WEST ANGELA V; DOWNING JENNIFER R; ERICSSON ANNA
权利人:FORMA THERAPEUTICS INC
摘要:The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.